ONCODES.PREC.MED. EO-34 (F:ZR8) — Stock Price
ONCODES.PREC.MED. EO-34 (F:ZR8) is currently trading at €0.30 EUR, down 0.33% today. Over the past 52 weeks, shares have ranged between €0.29 and €0.78. This page tracks ONCODES.PREC.MED. EO-34's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To understand the scale of the balance sheet behind this price, see ZR8 total assets.
ONCODES.PREC.MED. EO-34 (ZR8) Stock Price Chart — Daily History & Trading Volume
The chart below tracks ONCODES.PREC.MED. EO-34's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
ONCODES.PREC.MED. EO-34 Income Statement — Revenue, Profit & Earnings by Year
ONCODES.PREC.MED. EO-34's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Revenue | €207.04K | €1.07 Million | €7.98 Million | €3.83 Million |
| Cost of Revenue | €6.50 Million | €7.67 Million | €7.52 Million | €5.81 Million |
| Gross Profit | €-6.29 Million | €-6.60 Million | €459.51K | €-1.98 Million |
| Research & Development | — | — | — | — |
| SG&A | — | — | — | — |
| Total Operating Expenses | €8.01 Million | €11.02 Million | €9.59 Million | €7.56 Million |
| Operating Income | €-7.81 Million | €-9.94 Million | €-1.61 Million | €-3.73 Million |
| EBITDA | — | — | — | — |
| EBIT | — | — | — | — |
| Interest Expense | €438.79K | €146.63K | €116.50K | €355.93K |
| Income Before Tax | €-7.96 Million | €-9.86 Million | €-1.72 Million | €-4.08 Million |
| Income Tax Expense | — | — | — | — |
| Net Income | €-7.21 Million | €-8.09 Million | €-231.18K | €-2.94 Million |
ONCODES.PREC.MED. EO-34 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes ONCODES.PREC.MED. EO-34's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Assets | €10.71 Million | €16.63 Million | €18.37 Million | €8.37 Million |
| Total Current Assets | €8.67 Million | €14.40 Million | €16.41 Million | €6.53 Million |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | €4.84 Million | €10.01 Million | €125.00K | — |
| Net Receivables | €624.20K | €1.06 Million | €481.50K | €354.85K |
| Inventory | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | — | — | — | — |
| Total Liabilities | €11.14 Million | €12.94 Million | €6.59 Million | €4.17 Million |
| Total Current Liabilities | €3.61 Million | €4.11 Million | €3.96 Million | €1.21 Million |
| Long-term Debt | €7.20 Million | €8.83 Million | €2.60 Million | €2.91 Million |
| Net Debt | €7.14 Million | €8.50 Million | — | — |
| Total Stockholder Equity | €-429.39K | €3.69 Million | €11.78 Million | €4.20 Million |
| Retained Earnings | €-15.53 Million | €-8.32 Million | €-231.18K | €-2.94 Million |
ONCODES.PREC.MED. EO-34 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how ONCODES.PREC.MED. EO-34 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year |
|---|
| Operating Cash Flow |
| Capital Expenditures |
| Free Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
| Dividends Paid |
| Stock-Based Compensation |
| Depreciation |
| Change in Cash |
ONCODES.PREC.MED. EO-34 Earnings History — EPS Actual vs. Analyst Estimates
Track ONCODES.PREC.MED. EO-34's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for ONCODES.PREC.MED. EO-34.